

References:

American Diabetes Association Professional Practice Committee; 2. Diagnosis and Classification of Diabetes: *Standards of Care in Diabetes—2024*. *Diabetes Care* 1 January 2024; 47 (Supplement_1): S20–S42. <https://doi.org/10.2337/dc24-S002>

Donath MY. Type 1 diabetes: what is the role of autoimmunity in β cell death? *J Clin Invest*. 2022 Oct 17;132(20):e164460. doi: 10.1172/JCI164460. PMID: 36250460; PMCID: PMC9566895.

Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jeffrey P. Krischer, Åke Lernmark, Robert E. Ratner, Marian J. Rewers, Desmond A. Schatz, Jay S. Skyler, Jay M. Sosenko, Anette-G. Ziegler; Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care* 1 October 2015; 38 (10): 1964–1974. <https://doi.org/10.2337/dc15-1419>

Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., Herold, K. C., DiMeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Marks, J. B., Moore, W., Rodriguez, H., Russell, W. E., Schatz, D., ... Ziegler, A.-G. (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. *Science Translational Medicine*, 13(583). <https://doi.org/10.1126/scitranslmed.abc8980>

Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., & Herold, K. C. (2023). Teplizumab and β -cell function in newly diagnosed type 1 diabetes. *New England Journal of Medicine*. <https://doi.org/10.1056/nejmoa2308743>

TZIELD. Prescribing Information. Provention Bio, Inc.